All articles tagged with #tumor shrinkage
A small clinical trial demonstrated that an injectable experimental drug, 2141-V11, successfully shrank tumors and induced remission in some patients with aggressive breast and skin cancers, showing promise for future cancer treatments, though larger studies are needed.
A new study has found that COVID-19 may cause cancer tumors to shrink in mice, suggesting potential implications for cancer treatment research.
An experimental drug has shown promising results in shrinking pancreatic tumors by up to 70% in lab studies, offering hope for a more effective treatment for the aggressive and deadly cancer. The drug targets genetic drivers of pancreatic ductal adenocarcinomas, with researchers observing tumor shrinkage in 7 out of 10 models. This breakthrough comes as pancreatic cancer, which affects 67,000 Americans annually, has a low survival rate and is often diagnosed at late stages. Clinical trials will be crucial in determining the drug's potential to change the standard of care for pancreatic cancer patients.
Scientists are making advancements in the development of cancer treatment vaccines, which are shots designed to shrink tumors and prevent cancer from recurring. These experimental vaccines, including those using mRNA technology, aim to strengthen the immune system's ability to recognize and eliminate cancer cells. While early attempts at cancer vaccines faced challenges, researchers have gained valuable insights and are now focusing on patients with early-stage cancers. Additionally, vaccines that prevent certain types of cancer, such as liver cancer and cervical cancer, already exist. Ongoing studies are being conducted to test the effectiveness of personalized and broad-spectrum cancer vaccines in various types of cancer.
A nanofluidic drug-eluting seed (NDES) has been developed to deliver low-dose immunotherapy in the form of CD40 monoclonal antibodies (mAb) to shrink pancreatic cancer. The device protects the body from exposure to the powerful cancer drug and leads to fewer side effects. The tumor reduction was achieved with a "fourfold decrease" in drug dosage, making it a more focused therapy using less medication. The NDES device was inserted in one of two tumors in the same animal model, and shrinkage was noted in the tumor without the device, indicating that local treatment with immunotherapy activated the immune response to target other tumors.